Padideh Technology Development Center Makes Strategic Investment in State-of-the-Art Pharmaceutical Liquids and Supplements Factory

[City, Date] – In a transformative move aligned with the macro-strategy of the "Resistance Economy and Pharmaceutical Self-Sufficiency," the Padideh Technology Development Center has announced a multi-hundred billion Rial investment to establish the nation's most modern specialized factory for producing pharmaceutical liquids and supplements.

The massive project, currently under construction in an advanced industrial zone with a footprint of 1,300 square meters, is considered a milestone for the country's pharmaceutical industry. To delve into the details of this national project, we conducted an extensive interview with Engineer Ali Tarani, Chairman of the Padideh Technology Development Center.

Part 1: Strategic Necessity and Project Objectives

PR: Mr. Tarani, thank you for this opportunity. What factors led the Padideh Technology Development Center to enter the pharmaceutical sector?

Engineer Tarani: Greetings. Our entry into this field is based on meticulous studies and an assessment of the country's fundamental needs. We hope that with the operationalization of this project by 2025, the means to combat various diseases across the country will be significantly enhanced. Furthermore, based on its mission to comprehensively support health and pharmaceutical projects, the Center, in a joint investment with two knowledge-based and industrial companies, made this decision based on three main pillars:

• First: National Health Security – Unfortunately, in certain specialized areas like pharmaceutical liquids and supplements, we have a significant dependence on imports, which under sanctions can pose a threat to public health.

• Second: Technology-Centric Approach – We believe the future of the pharmaceutical industry lies in the integration of biotechnology, nanotechnology, and advanced engineering, and there is substantial domestic capacity in this area.

• Third: Social Responsibility – As a technology-driven institution, we feel obligated to use our capabilities to enhance the health standards of society.

PR: What is the technical and economic rationale for the factory's specific focus on pharmaceutical liquids and supplements?

Engineer Tarani: This choice is entirely strategic and based on field studies. Pharmaceutical liquids, including syrups, suspensions, and injectable solutions, hold a special position due to their:

• Very wide range of consumption across different age groups

• Necessity for adhering to very high production standards

• Requirement for complex technologies in sterilization and preservation
  Additionally, pharmaceutical supplements have a growing market, given changing lifestyle patterns and increased attention to preventive health.

Part 2: Technical and Technological Features

PR: Please tell us about the technical and technological features of this project.

Engineer Tarani: This factory is being designed and built with three distinguishing features:

• Integrated Automation System: From raw material intake to final packaging, the process will be fully automated, ensuring consistent quality and reducing human error.

• Clean Rooms Class A and B: For producing sterile products, the most advanced systems for controlling microbial and particulate contamination will be used.

• Multi-layered Quality Control System: Utilizing advanced analytical instruments like HPLC and GC-MS, quality will be meticulously monitored at every stage of production.

PR: What is the current phase of the project and what is its timeline?

Engineer Tarani: The project is progressing at a remarkable pace:

• Phase 1 (Land procurement and design): Completed.

• Phase 2 (Structure and infrastructure construction): Ongoing, with 70% physical progress.

• Phase 3 (Machinery installation): Machinery sourced from Europe and Japan is currently being transported.

• Phase 4 (Licensing): Currently obtaining licenses from the Food and Drug Organization and international standards bodies.
  We anticipate full operationalization by the end of 2024, with the first shipment of our products reaching the market by the first quarter of 2025.

Part 3: Economic and Social Impact

PR: What impact will this investment have on job creation?

Engineer Tarani: This project will be an economic driver for the region:

• Direct Employment: For 80 specialized graduates in pharmaceuticals, chemistry, chemical engineering, biomedical engineering, and IT.

• Indirect Employment: In logistics, commerce, services, and support for approximately 120 people.

• Training Program: A specialized apprenticeship program for 200 local individuals.

PR: Will this project affect the pricing of pharmaceutical products?

Engineer Tarani: Absolutely! By eliminating heavy import and international transportation costs, and by using domestic raw materials where possible, we will be able to offer products with higher quality and at a 20-30% lower price than similar foreign equivalents. This will directly benefit patients and the national health system.

Part 4: Future Outlook and Expansion Plans

PR: What are your plans for developing this project in the future?

Engineer Tarani: We see this project as the start of a larger transformation:

• Production Line Expansion: In the second phase, we plan to produce biotechnological drugs and nano-medicines.

• Exports to Regional Countries: Targeting 5 neighboring countries, we will begin export operations in the second year of production.

• Research Center: Establishing a specialized R&D center alongside the factory to develop new formulations.

PR: What is your message for potential investors and partners?

Engineer Tarani: We are focused on networking and strategic collaborations. We invite all interested knowledge-based companies, specialists, and investors to join this innovation ecosystem. Together, we can create an advanced pharmaceutical hub in the region.

Part 5: Innovation and Project Distinctions

PR: What specific innovations will this project incorporate?

Engineer Tarani: We have several unique innovations in this project:

• QR Code on each product: Enabling complete traceability from the production line to the pharmacy.

• Smart Packaging: With the capability to indicate expiration dates and unsuitable storage conditions.

• Flexible Production Line: Capable of producing small, high-variety batches to meet specific market needs.

Concluding Remarks

PR: Any final words?

Engineer Tarani: At the Padideh Technology Development Center, we are completing the acceleration chain and invite technologists, creative companies, and knowledge-based firms from across the country to present their knowledge-based projects at this Center, so that the grounds for their further growth and commercialization can be provided.

PR: We sincerely thank you for your valuable time. We wish you and all those involved in this national project great success.